Literature DB >> 11323041

Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda.

R H Gray1, M J Wawer, R Brookmeyer, N K Sewankambo, D Serwadda, F Wabwire-Mangen, T Lutalo, X Li, T vanCott, T C Quinn.   

Abstract

BACKGROUND: The probability of HIV-1 transmission per coital act in representative African populations is unknown. We aimed to calculate this probability overall, and to estimate how it is affected by various factors thought to influence infectivity.
METHODS: 174 monogamous couples, in which one partner was HIV-1 positive, were retrospectively identified from a population cohort in Rakai, Uganda. Frequency of intercourse and reliability of reporting within couples was assessed prospectively. HIV-1 seroconversion was determined in the uninfected partners, and HIV-1 viral load was measured in the infected partners. Adjusted rate ratios of transmission per coital act were estimated by Poisson regression. Probabilities of transmission per act were estimated by log-log binomial regression for quartiles of age and HIV-1 viral load, and for symptoms or diagnoses of sexually transmitted diseases (STDs) in the HIV-1-infected partners.
RESULTS: The mean frequency of intercourse was 8.9 per month, which declined with age and HIV-1 viral load. Members of couples reported similar frequencies of intercourse. The overall unadjusted probability of HIV-1 transmission per coital act was 0.0011 (95% CI 0.0008-0.0015). Transmission probabilities increased from 0.0001 per act at viral loads of less than 1700 copies/mL to 0.0023 per act at 38 500 copies/mL or more (p=0.002), and were 0.0041 with genital ulceration versus 0.0011 without (p=0.02). Transmission probabilities per act did not differ significantly by HIV-1 subtypes A and D, sex, STDs, or symptoms of discharge or dysuria in the HIV-1-positive partner.
INTERPRETATION: Higher viral load and genital ulceration are the main determinants of HIV-1 transmission per coital act in this Ugandan population.

Entities:  

Mesh:

Year:  2001        PMID: 11323041     DOI: 10.1016/S0140-6736(00)04331-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  432 in total

1.  Confronting global AIDS: prevention and treatment.

Authors:  A Berkman
Journal:  Am J Public Health       Date:  2001-09       Impact factor: 9.308

2.  Global voices on HIV/AIDS. Unfairness of social and economic structures affect AIDS in Africa.

Authors:  Dorothy Logie
Journal:  BMJ       Date:  2002-04-27

3.  Scaling up circumcision programs in Southern Africa: the potential impact of gender disparities and changes in condom use behaviors on heterosexual HIV transmission.

Authors:  Kyeen M Andersson; Douglas K Owens; A David Paltiel
Journal:  AIDS Behav       Date:  2011-07

Review 4.  Immune modulation during latent herpesvirus infection.

Authors:  Douglas W White; R Suzanne Beard; Erik S Barton
Journal:  Immunol Rev       Date:  2012-01       Impact factor: 12.988

5.  Enzymatic triggered release of an HIV-1 entry inhibitor from prostate specific antigen degradable microparticles.

Authors:  Meredith R Clark; Hyder A Aliyar; Chang-won Lee; Julie I Jay; Kavita M Gupta; Karen M Watson; Russell J Stewart; Robert W Buckheit; Patrick F Kiser
Journal:  Int J Pharm       Date:  2011-04-12       Impact factor: 5.875

6.  Expression of Haemophilus ducreyi collagen binding outer membrane protein NcaA is required for virulence in swine and human challenge models of chancroid.

Authors:  Robert A Fulcher; Leah E Cole; Diane M Janowicz; Kristen L Toffer; Kate R Fortney; Barry P Katz; Paul E Orndorff; Stanley M Spinola; Thomas H Kawula
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

7.  The second wave will drown us.

Authors:  Michael Gross
Journal:  Am J Public Health       Date:  2003-06       Impact factor: 9.308

Review 8.  The role of infant immune responses and genetic factors in preventing HIV-1 acquisition and disease progression.

Authors:  C Farquhar; G John-Stewart
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

9.  Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial.

Authors:  Frederick L Altice; Duncan Smith-Rohrberg Maru; R Douglas Bruce; Sandra A Springer; Gerald H Friedland
Journal:  Clin Infect Dis       Date:  2007-08-13       Impact factor: 9.079

10.  A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV Infection.

Authors:  Lesia K Dropulic; Makinna C Oestreich; Harlan L Pietz; Kerry J Laing; Sally Hunsberger; Keith Lumbard; Doreen Garabedian; Siu Ping Turk; Aiying Chen; Ronald L Hornung; Chetan Seshadri; Malisa T Smith; Nancy A Hosken; Sanjay Phogat; Lee-Jah Chang; David M Koelle; Kening Wang; Jeffrey I Cohen
Journal:  J Infect Dis       Date:  2019-08-09       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.